Answers are grounded in this paper and cite their sources.
Single-center cohort analysis demonstrates reduced risks and improved efficiency with in-series therapy.
Our approach to providing "in-series" CRRT and TPE used existing access and circuits, a single device, and resulted in efficient treatments, reduced infection risk, reduced exposure to circuits, less hemodilution, and less blood product use. Small potential cost and waste reductions were also achieved. This approach was performed safely with no unexpected adverse events.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: